S

Sesen Bio Inc
F:PCBK

Watchlist Manager
Sesen Bio Inc
F:PCBK
Watchlist
Price: 0.5124 EUR 28.1%
Market Cap: 103.9m EUR

Net Margin

-57.8%
Current
Declining
by 4.6%
vs 3-y average of -53.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-57.8%
=
Net Income
$-19.9m
/
Revenue
$40m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-57.8%
=
Net Income
€-19.9m
/
Revenue
$40m

Peer Comparison

Country Company Market Cap Net
Margin
US
Sesen Bio Inc
F:PCBK
103.9m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 82% of companies in the United States of America
Percentile
18th
Based on 15 072 companies
18th percentile
-57.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Sesen Bio Inc
Glance View

Market Cap
103.9m EUR
Industry
Biotechnology

Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).

PCBK Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-57.8%
=
Net Income
$-19.9m
/
Revenue
$40m
What is Sesen Bio Inc's current Net Margin?

The current Net Margin for Sesen Bio Inc is -57.8%, which is below its 3-year median of -53.2%.

How has Net Margin changed over time?

Over the last 2 years, Sesen Bio Inc’s Net Margin has increased from -245.1% to -57.8%. During this period, it reached a low of -245.1% on Dec 1, 2020 and a high of -1.4% on Dec 31, 2021.

Back to Top